J Korean Med Sci.  2011 Apr;26(4):574-576. 10.3346/jkms.2011.26.4.574.

Pulmonary BALT Lymphoma Successfully Treated with Eight Cycles Weekly Rituximab: Report of First Case and F-18 FDG PET/CT Images

• Bilici A
• Seker M
• Ustaalioglu BBO
• Canpolat N
• Salepci T
• Gumus M

• KMID: 1777890
• DOI: http://doi.org/10.3346/jkms.2011.26.4.574

Abstract

Extra marginal-zone lymphomas of the lung is a very rare tumor and it originates from bronchial-associated lymphoid tissue. A 68-yr-old woman presented with productive cough and dyspnea. A thorax computed tomography scan showed a 9 x 10 cm in size mass in the left lung and pleural effusion in the lower lobe of left lung. Positron emission tomography/computed tomography (PET/CT) revealed intense uptake foci at the upper and middle sites of left lung and slight uptake foci at the mediastinal lymph nodes which showed malignant involvement. After bronchoscopic biopsy, the diagnosis of pulmonary bronchial-associated lymphoid tissue (BALT) lymphoma was confirmed. At the end of the eight cycles weekly rituximab treatment, complete response was obtained by PET/CT findings. It is concluded that extended rituximab schedule is more effective and it would be beneficial to investigate the use of PET/CT in the diagnosis and evaluating of the treatment response of pulmonary BALT lymphoma.

Keyword

BALT lymphoma; Rituximab; Extended Schedule; Positron-Emission Tomography

MeSH Terms

Aged
Antibodies, Monoclonal, Murine-Derived/*administration & dosage
Antineoplastic Agents/*administration & dosage
Drug Administration Schedule
Female
Fluorodeoxyglucose F18/*diagnostic use
Humans
Lung Neoplasms/*drug therapy/pathology/radionuclide imaging
Lymphoma, B-Cell, Marginal Zone/*drug therapy/pathology/radionuclide imaging
Positron-Emission Tomography
Radiopharmaceuticals/*diagnostic use
Tomography, X-Ray Computed

Figure

• 

  Fig. 1 Images by PET/CT scanning. (A) Diffuse hypermetabolic involvement (standard uptake value [SUV]:7.2) at the upper and middle site of the left lung and mild uptake foci at the mediastinal lymph nodes (SUV:3.4) which was compatible with malignancy. (B) Partial response after the sixth cycles rituximab. (C) Complete remission after eight cycles of rituximab medication.

Reference

1. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol. 2005. 23:6415–6420.

2. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994. 84:1361–1392.

3. Zucca E, Roggero E, Pileri S. B-cell lymphoma of MALT type: a review with special emphasis on diagnostic and management problems of low-grade gastric tumours. Br J Haematol. 1998. 100:3–14.

4. Chung JJ, Kim MJ, Kie JH, Kim KW. Mucosa-associated lymphoid tissue lymphoma of the esophagus coexistent with bronchus-associated lymphoid tissue lymphoma of the lung. Yonsei Med J. 2005. 46:562–566.

5. Isaacson PG. Mucosa-associated lymphoid tissue lymphoma. Semin Hematol. 1999. 36:139–147.

6. Sminia T, van der Brugge-Gamelkoorn GJ, Jeurissen SH. Structure and function of bronchus-associated lymphoid tissue (BALT). Crit Rev Immunol. 1989. 9:119–150.

7. Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Crump M. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys. 2001. 50:1258–1264.

8. Choi WS, Cho JH, Hwang YI, Jang SH, Kim DG, Jun SY, Min K, Lee IJ, Lee JW, Jung KS. A case of bronchus-associated lymphoid tissue (BALT) lymphoma treated with lobectomy. Tuberc Respir Dis. 2007. 62:427–431.

9. Song SY, Choi EK, Kim JH, Ahn SD, Shin SS, Lee S. Radiation therapy for bronchial associated lymphoid tissue (BALT) lymphoma: a case report. J Lung Cancer. 2006. 5:114–117.

10. Seker M, Bilici A, Ustaalioglu BO, Salman T, Sonmez B, Canpolat NA, Salepci T, Gumus M, Yaylaci M. Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma. Leuk Res. 2009. 33:e154–e156.

11. Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC. Primary non-Hodgkin's lymphoma of the lung. Ann Thorac Surg. 2000. 69:993–997.

12. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005. 31:456–473.

13. Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003. 102:2741–2745.

14. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD 20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999. 17:268–276.

15. Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V. Extended Rituximab (anti-CD 20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999. 10:655–661.

16. Chong EA, Svoboda J, Cherian S, Andreadis C, Downs LH, Zhuang H, Alavi A, Tsai DE, Schuster SJ. Regression of pulmonary MALT lymphoma after treatment with rituximab. Leuk Lymphoma. 2005. 46:1383–1386.

17. Ahmed S, Kussick SJ, Siddiqui AK, Bhuiya TA, Khan A, Sarewitz S, Steinberg H, Sison CP, Rai KR. Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease. Eur J Cancer. 2004. 40:1320–1326.

18. Stefanovic A, Morgensztern D, Fong T, Lossos IS. Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database. Leuk Lymphoma. 2008. 49:1311–1320.

19. Arkenau HT, Gordon C, Cunningham D, Norman A, Wotherspoon A, Chau I. Mucosa associated lymphoid tissue lymphoma of the lung: the Royal Marsden Hospital experience. Leuk Lymphoma. 2007. 48:547–550.

20. Seker M, Ustaalioğlu BB, Bilici A, Yildirim ME, Kefeli U, Barisik NO, Tamer I, Gumus M. Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma. Leuk Res. 2010. 34:e160–e163.